Sign In
Buy APTX
$0.0960
+0 (+0%)
At Close: Mar 28, 2024
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia
07:15am, Friday, 12'th Aug 2022
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, to
Aptinyx Inc. (APTX) CEO Andy Kidd on Q2 2022 Results - Earnings Call Transcript
07:13am, Sunday, 07'th Aug 2022
Aptinyx Inc. (NASDAQ:APTX ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Patrick Flavin - Senior Manager, Corporate Development & Investor Relations Andy Kidd - Pres
Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights
04:05pm, Thursday, 04'th Aug 2022
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, to
Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022
07:47am, Friday, 15'th Jul 2022
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, to
Aptinyx to Participate in H.C. Wainwright Global Investment Conference
07:37am, Wednesday, 18'th May 2022
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announ
Aptinyx, Inc. (APTX) CEO Andy Kidd on Q1 2022 Results - Earnings Call Transcript
12:50pm, Friday, 13'th May 2022
Aptinyx, Inc. (NASDAQ:APTX ) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Pat Flavin - IR Andy Kidd - CEO Ashish Khanna - CFO Kathryn King - SVP of Clinical and CMC op
Aptinyx to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
07:47am, Wednesday, 27'th Apr 2022
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, to
Aptinyx (APTX) Tanks as Neuropathic Pain Study Misses Goal
12:47pm, Friday, 08'th Apr 2022
Aptinyx's (APTX) phase IIb study evaluating the effects of NYX-2925 in patients with painful diabetic peripheral neuropathy misses the primary endpoint. Stock falls sharply.
Aptinyx Shares Tank On Disappointed Data From Mid-Stage Diabetic Peripheral Neuropathy Study
09:36am, Thursday, 07'th Apr 2022
Aptinyx Inc (NASDAQ: APTX) shares are plunging after results from a Phase 2b study of NYX-2925 in patients with painful diabetic peripheral neuropathy (DPN). NYX-2925 did not achieve statistically
Aptinyx's stock falls 48% after drug fails in Phase 2b trial
08:44am, Thursday, 07'th Apr 2022
Shares of Aptinyx Inc. APTX, -4.49% tumbled 48.7% in premarket trading on Thursday after the company said an experimental treatment for painful diabetic peripheral neuropathy failed to meet the primar
7 Biotech Stocks to Buy With Key Catalysts for April
06:59am, Tuesday, 05'th Apr 2022
Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies bel
Aptinyx, Inc. (APTX) CEO Andy Kidd on Q4 2021 Results - Earnings Call Transcript
10:56pm, Wednesday, 23'rd Mar 2022
Aptinyx, Inc. (APTX) CEO Andy Kidd on Q4 2021 Results - Earnings Call Transcript
Has Aptinyx Inc. (APTX) Outpaced Other Medical Stocks This Year?
11:17am, Monday, 21'st Mar 2022
Here is how Aptinyx Inc. (APTX) and Doximity (DOCS) have performed compared to their sector so far this year.
Aptinyx to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, March 23, 2022
12:47pm, Wednesday, 09'th Mar 2022 Business Wire
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Wednesday, March 23, 2022 at 5:00 p.m. ET to report fourth quarter and full year 2021 financial results and discuss recent business highlights. To access the live conference call, please dial (844) 200-6205 (domestic) or
Aptinyx to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, March 23, 2022
07:47am, Wednesday, 09'th Mar 2022
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, to
